Essentials for Clinicians: Breast Cancer - Editors and Contributors

Editors

  • Fatima Cardoso, Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
  • Vesa Kataja, Central Finland Health Care District, Jyväskylä Central Hospital, Jyväskylä, Finland
  • Vivianne Tjan-Heijnen, Maastricht University Medical Centre, Maastricht, Netherlands

Series editor: Michele Ghielmini, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland

Contributors

Chapter 1 - Diagnosis and Staging of Breast Cancer and Multidisciplinary Team Working

  • H Joensuu - Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland
  • M Leidenius - Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland

Chapter 2 - Pathology (Including Normal Breast) and Disease Subtypes

  • G Viale - Department of Pathology and Laboratory Medicine, European Institute of Oncology, Milan; University of Milan School of Medicine, Milan, Italy
  • MG Mastropasqua - Department of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy

Chapter 3 - Management of Carcinoma In Situ

  • M-J Cardoso - Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
  • C Vrieling - Department of Radiation Oncology, Clinique des Grangettes, Geneva, Switzerland

Chapter 4 - Breast Cancer Surgery

  • P Dubsky - Department of Surgery, Medical University of Vienna, Vienna, Austria; Breast Centre, St. Anna, Lucerne, Switzerland
  • W Haslik - Division of Plastic and Reconstructive Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria

Chapter 5 - Breast Cancer Radiotherapy

  • I Kunkler - Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK
  • V Kataja - Central Finland Health Care District, Jyväskylä Central Hospital, Jyväskylä, Finland

Chapter 6 - Adjuvant Systemic Therapies for Breast Cancer (Including Follow-up)

  • N Turner -‘Sandro Pitigliani’ Medical Oncology Department, Prato Hospital, Istituto Toscano Tumori, Prato, Italy
  • CD Hart - ‘Sandro Pitigliani’ Medical Oncology Department, Prato Hospital, Istituto Toscano Tumori, Prato, Italy
  • L Biganzoli - ‘Sandro Pitigliani’ Medical Oncology Department, Prato Hospital, Istituto Toscano Tumori, Prato, Italy
  • R Blum - ‘Sandro Pitigliani’ Medical Oncology Department, Prato Hospital, Istituto Toscano Tumori, Prato, Italy
  • M Pestrin - ‘Sandro Pitigliani’ Medical Oncology Department, Prato Hospital, Istituto Toscano Tumori, Prato, Italy
  • A Di Leo - ‘Sandro Pitigliani’ Medical Oncology Department, Prato Hospital, Istituto Toscano Tumori, Prato, Italy

Chapter 7 - Neoadjuvant Chemotherapy and Management of Locally Advanced Disease

  • C Fontanella - German Breast Group, Neu-Isenburg, Germany; Department of Oncology, University Hospital of Udine, Udine, Italy
  • G von Minckwitz - German Breast Group, Neu-Isenburg; University Women’s Hospital, Frankfurt; Senologic Oncology, Düsseldorf, Germany

Chapter 8 - Management of Metastatic Disease (Including Response Assessment)

  • E Senkus - Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland
  • A Łacko - Department of Clinical Oncology, Wroclaw Medical University, Wrocław, Poland

 Chapter 9 - Epidemiology of Breast Cancer

  • M Pollán - Cancer and Environmental Epidemiology Unit, National Center of Epidemiology (Pab. 12), Instituto de Salud Carlos III, Madrid, Spain

Chapter 10 - Screening for Breast Cancer

  • V Kataja - Central Finland Health Care District, Jyväskylä Central Hospital, Jyväskylä, Finland

Chapter 11 - Genetic Counselling and Testing

  • O Pagani - Genetic Counselling Service of the Institute of Oncology of Southern Switzerland, Lugano, Switzerland

Chapter 12 - Prognostic and Predictive Factors

  • F Penault-Llorca - Centre Régional de Lutte Contre le Cancer d’Auvergne, Clermont-Ferrand, France

Chapter 13 - New Targets and New Drugs for Breast Cancer

  • G Curigliano - Division of Experimental Cancer Medicine, Istituto Europeo di Oncologia, Milan, Italy

Chapter 14 - Organ-specific Problems in Metastatic Breast Cancer

  • T Cufer - University Clinic Golnik, Golnik, Slovenia

Chapter 15 - Metastatic Breast Cancer in Men

  • F Cardoso - Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
  • B Sousa - Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal

Chapter 16 - Breast Cancer at the Extremes of Age

Part A: Breast Cancer in Young Women

  • S Paluch-Shimon - Breast Oncology Unit, Division of Oncology, Shaare Zedek Medical Centre, Jerusalem, Israel

Part B: Breast Cancer in the Elderly

  • H Wildiers - University Hospitals Leuven, Department of General Medical Oncology, Leuven, Belgium

Chapter 17 - Locally Recurrent Disease

  • H Crezee - Department of Radiation Oncology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
  • O Kaidar-Person - Department of Oncology, Radiation Oncology Unit, Rambam Health Care Campus, Haifa, Israel
  • P Poortmans - Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, Netherlands; Institut Curie, Paris, France

Declarations of interest

  • L Biganzoli: No conflicts of interest.
  • R Blum: No conflicts of interest.
  • F Cardoso: No conflicts of interest.
  • M-J Cardoso: No conflicts of interest.
  • H Crezee: No conflicts of interest.
  • T Cufer: No conflicts of interest.
  • G Curigliano: Expert testimony for Pfizer, Novartis, Roche Genentech; Member of the Steering committee for randomised clinical trials of Cascadian, Roche Genentech, MacroGenics.
  • A Di Leo: No conflicts of interest.
  • P Dubsky: No conflicts of interest.
  • C Fontanella: No conflicts of interest.
  • CD Hart: No conflicts of interest.
  • W Haslik: No conflicts of interest.
  • H Joensuu: No conflicts of interest.
  • O Kaidar-Person: No conflicts of interest.
  • V Kataja: No conflicts of interest.
  • I Kunkler: No conflicts of interest.
  • A Łacko: Honoraria from AstraZeneca, Novartis, Roche; travel support from Roche.
  • M Leidenius: No conflicts of interest.
  • MG Mastropasqua: No conflicts of interest.
  • O Pagani: No conflicts of interest.
  • S Paluch-Shimon: No conflicts of interest.
  • F Penault-Llorca: No conflicts of interest.
  • M Pestrin: No conflicts of interest.
  • M Pollán: No conflicts of interest.
  • P Poortmans: No conflicts of interest.
  • E Senkus: Honoraria from AstraZeneca, Celgene, Pfizer, Roche; travel support from Amgen, AstraZeneca, Pfizer, Roche.
  • B Sousa: No conflicts of interest.
  • N Turner: No conflicts of interest.
  • G Viale: No conflicts of interest.
  • G von Minckwitz: Research grants from GlaxoSmithKline, Novartis, Roche, Teva, Sanofi-Aventis.
  • C Vrieling: No conflicts of interest.
  • H Wildiers: No conflicts of interest.

« Previous Page Next Page »

Last update: 13 October 2017